Атеросклероз спонтанный и прогрессирующий – есть ли разница?
https://doi.org/10.15372/ATER20200409
Аннотация
В статье проанализировано состояние проблемы быстропрогрессирующего атеросклероза в сравнении со спонтанным, или классическим, течением заболевания. Выделены наиболее известные факторы, обусловливающие ускоренное течение атеросклероза, и перспективы терапевтического воздействия. В анализе использованы данные из публикаций за последние пять лет на основе баз данных PubMed, Google Scholar и РИНЦ.
Об авторах
Н. Г. Ложкина
ФГБОУ ВО Новосибирский государственный медицинский университет Минздрава России
Россия
Россия
д-р мед. наук, проф. кафедры факультетской терапии, кардиолог и куратор отделения для лечения больных с острым коронарным синдромом Регионального сосудистого центра ¹ 1,
SPIN-код: 5320-7554
630091, г. Новосибирск, Красный пр., 52
О. М. Пархоменко
ФГБОУ ВО Новосибирский государственный медицинский университет Минздрава России
Россия
Россия
зам. главного врача по терапии ГБУЗ «Городская клиническая больница ¹ 1»
SPIN-код: 0000-0000
630091, г. Новосибирск, Красный пр., 52
Список литературы
1. Piepoli M. F., Hoes A. W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M., Corrà U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D.R., Løchen M.L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur. Heart J., 2016; 37: 2315–2381. doi: 10.1093/eurheartj/ehw106
2. Hasturk H., Abdallah R., Kantarci A., Nguyen D., Giordano N., Hamilton J., van Dyke T.E. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2015; 35(5): 1123–1133. doi: 10.1161/ATVBAHA.115.305324
3. Herrington W., Lacey B., Sherliker P., Armitage J., Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ. Res., 2016 Feb 19; 118 (4): 535–546. doi: 10.1161/CIRCRESAHA.115.307611. PMID: 26892956
4. Rea I.M., Gibson D.S., McGilligan V., McNerlan S.E., Alexander H.D., Ross O.A. Age and age-related diseases: role of inflammation triggers and cytokines. Front. Immunol., 2018. doi: 10.3389/fimmu.2018.00586
5. Dierickx D., Tousseyn T., Olivier G. How I treat posttransplant lymphoproliferative disorders. Blood, 2015; 126 (20): 2274–2283. doi: 10.1182/blood-2015-05-615872
6. Haverich A. A surgeon’s view on the pathogenesis of atherosclerosis. Circulation, 2017; 135 (3): 205–207. doi: 10.1161/CIRCULATIONAHA.116.025407
7. Gimbrone Jr M.A. García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res., 2016; 118: 620–636. doi: 10.1161/CIRCRESAHA.115.306301
8. Song P., Fang Z., Wang H., Cai Y., Rahimi K., Zhu Y., Fowkes F.G.R., Fowkes F.J.I., Rudan I. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, metaanalysis, and modelling study. Peige Song, 2020; 8 (5): E721–E729. doi: 10.1016/S2214-109X (20) 30117-0
9. Motoyama S., Ito H., Sarai M., Kondo T., Kawai H., Nagahara Y., Harigaya H., Kan S., Annj H., Takahashi H., Naruse H., Ishii J., Hecht H., Shaw L.J., Ozaki Y., Narula J. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J. Am. Coll. Cardiol., 2015; 66: 337–346. doi: 10.1016/j.jacc.2015.05.069
10. Ahmadi A., Leipsic J., Blankstein R., Taylor C., Hecht H., Stone G.W., Narula J. Do plaques rapidly progress prior to myocardial infarction? The interplay between plaque vulnerability and progression. Circ. Res., 2015; 117: 99. doi: 10.1161/CIRCRESAHA.117.305637
11. Ahmadi A., Narula J. Precluding revascularization in stable coronary disease: the power of double negatives. J. Am. Coll. Cardiol., 2018; 72: 1936. doi: 10.1016/j.jacc.2018.08.1040
12. Park H.B., Heo R., ó Hartaigh B., Cho I., Gransar H., Nakazato R., Leipsic J., Mancini G.B.J., Koo B.-K., Otake H., Budoff M.J., Berman D.S., Erglis A., Chang H.-J., Min J.K. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. J. Am. Coll. Cardiol. Img., 2015; 8: 1–10. doi: 10.1016/j.jcmg.2014.11.002
13. Ferencik M., Mayrhofer T., Bittner D.O., Emami H., Puchner S.B., Lu M.T., Meyersohn N.M., Ivanov A.V., Adami E.C., Patel M.R., Mark D.B., Udelson J.E., Lee K.L., Douglas P.S., Hoffmann U. Use of highrisk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol., 2018; 3: 144–152. doi: 10.1001/jamacardio.2017.4973
14. Ahmadi A., Leipsic J., Øvrehus K.A., Gaur S., Bagiella E., Ko B., Dey D., LaRocca G., Jensen J.M., Bøtker H.E., Achenbach S., de Bruyne B., Nørgaard B.L., Narula J. Lesion-specific and vessel-related determinants of fractional flow reserve beyond coronary artery stenosis. J. Am. Coll. Cardiol. Img., 2018; 11: 521–530. doi: 10.1016/j.jcmg.2017.11.020
15. Boyle E.C., Sedding D.G., Haverich A. Targeting vasa vasorum dysfunction to prevent atherosclerosis. Vascul. Pharmacol., 2017; 96–98: 5–10. doi: 10.1016/j.vph.2017.08.003
16. Ahmadi A., Stone G.W., Leipsic J., Serruys P.W., Shaw L., Hecht H., Wong G., Nørgaard B.L., Gara P.T.O., Chandrashekhar Y., Narula J. Association of coronary stenosis and plaque morphology with fractional flow reserve and outcomes. JAMA Cardiol., 2016; 1: 350. doi: 10.1001/jamacardio.2016.0263
17. Lee S.E., Chang H.J., Sung J.M., Park H.-B., Heo R., Rizvi A., Lin F.Y., Kumar A., Hadamitzky M., Kim Y.J., Conte E., Andreini D., Pontone G., Budoff M.J., Gottlieb I., Lee B.K., Chun E.J., Cademartiri F., Maffei E., Marques H., Leipsic J.A., Shin S., Choi J.H.,Chinnaiyan K., Raff G., Virmani R., Samady H., Stone P.H., Berman D.S., Narula J., Shaw L.J., Bax J.J., Min J.K. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. J. Am. Coll. Cardiol. Img., 2018; 11 (10): 1475–1484. doi:
18. 1016/j.jcmg.2018.04.015
19. Ahmadi A., Narula J. Primary and secondary prevention, or subclinical and clinical atherosclerosis. J. Am. Coll. Cardiol. Img., 2017; 10 (4): 447–450. doi: 10.1016/j.jcmg.2016.08.002
20. Shah P., Bajaj S., Virk H., Bikkina M. Rapid progression of coronary atherosclerosis: a review. Thrombosis, 2015; 2: 1–6. doi: 10.1155/2015/634983
21. Chistiakov D.A., Melnichenko A.A., Myasoedova V.A., Grechko A.V., Orekhov A.N. Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis. Ann. Med., 2017; 49 (8): 661–677. doi: 10.1080/07853890.2017.1366041
22. Singh A., Collins B.L., Gupta A., Fatima A., Qamar A., Biery D., Baez J., Cawley M., Klein J., Hainer J., Plutzky J., Cannon C.P., Nasir K., di Carli M.F., Bhatt D.L., Blankstein R. Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry. J. Am. Coll. Cardiol., 2018; 71 (3): 292–302. doi: 10.1016/j.jacc.2017.11.007
23. Mitchell J.D., Fergestrom N., Gage B.F., Paisley R., Moon P., Novak E., Cheezum M., Shaw L.J., Villines T.C. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J. Am. Coll. Cardiol., 2018; 72 (25): 3233–3242. doi: 10.1016/j.jacc.2018.09.051
24. Tsujita K., Sugiyama S., Sumida H., Shimomura H., Yamashita T., Yamanaga K., Komura N., Sakamoto K., Oka H., Nakao K., Nakamura S., Ishihara M., Matsui K., Sakaino N., Nakamura N., Yamamoto N., Koide S., Matsumura T., Fujumoto K., Tsunoda R., Morikami Y., Matsuyama K., Oshima S., Kaikita K., Hokimoto S., Ogawa H. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J. Am. Coll. Cardiol., 2015; 66 (5): 495–507. doi: 10.1016/j.jacc.2015.05.065
25. Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., Jüni P., Kastrati A. Kolh P., Mauri L., Montalescot G., Neumann F.-J., Petricevic M., Roffi M., Steg P.G., Windecker S., Zamorano J.L., Levine G.N. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J., 2018; 39 (3): 213–260. doi: 10.1093/eurheartj/ehx419
26. Xu J., Lu X., Shi G.-P. Vasa vasorum in atherosclerosis and clinical significance. Int. J. Mol. Sci., 2015; 16 (5): 11574–11608. doi: 10.3390/ijms160511574
27. Zheng L., Yang W.J., Niu C.B., Zhao H.L., Wong K.S., Leung T.W.H., Chen X.Y. Correlation of adventitial vasa vasorum with intracranial atherosclerosis: a postmortem study. J. Stroke, 2018; 20 (3): 342–349. doi: 10.5853/jos.2018.01263
28. Alfonso F., de la Torre Hernández J.M. Vasa vasorum and coronary artery disease progression: optical coherence tomography findings. Eur. Heart J. Cardiovasc. Img., 2016; 17 (3): 280–282. doi: 10.1093/ehjci/jev318
29. Boyle E.C., Sedding D.G., Haverich A. Targeting vasa vasorum dysfunction to prevent atherosclerosis. Vascul. Pharmacol., 2017; 96–98: 5–10. doi: 10.1016/j.vph.2017.08.003
30. Colas R.A., Souza P.R., Walker M.E., Burton M., Zaslona Z., Curtis A.M., Marques R.M., Dalli J. Impaired production and diurnal regulation of vascular RvDn-3 DPA increase systemic inflammation and cardiovascular disease. Circ. Res., 2018; 122(6): 855–863. doi: 10.1161/CIRCRESAHA.117.312472
31. Hansson G.K., Libby P., Tabas I. Inflammation and plaque vulnerability. J. Int. Med., 2015; 278 (5): 483–493. doi: 10.1111/joim.12406
32. Kral B.G., Kalyani R.R., Yanek L.R. Relation of plasma lipoprotein(a) to subclinical coronary plaque volumes, three-vessel and left main coronary disease, and severe coronary stenoses in apparently healthy african americans with a family history of early onset coronary artery disease. Am. J. Cardiol., 2016; 118 (5): 656–661. doi: 10.1016/j.amjcard.2016.06.020
33. Rincón I., Polak J.F., O'Leary D.H., Battafarano D.F., Erikson J.M., Restrepo J.F., Molinf E., Escalante A. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann. Rheum. Dis., 2015; 74: 1118–1123. doi: 10.1136/annrheumdis-2013-205058
34. Welsh P., Grassia G., Botha S., Sattar N., Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br. J. Pharmacol., 2017; 174 (22): 3898–3913. doi: 10.1111/bph.13818
35. Shin S., Park H.B., Chang H.J., Arsanjani R., Min J.K., Kim Y.-J., Lee B.K., Choi J.-H., Hong G.-R., Chung N. Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study. JACC Img., 2017; 10 (4): 437–446. doi: 10.1016/j.jcmg.2016.04.013
36. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D., Kastelein J.J.P., Cornel J.H., Pais P., Pella D., Genest J., Cifkova R., Lorenzatti A., Forster T., Kobalava Z., Vida-Smiti L., Flather M., Shimokawa H., Ogawa H., Dellborg M., Rossi P.R.F., Troquay R.P.T., Libby P., Glynn R.J.G. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med., 2017; 377 (12): 1119–1131. doi: 10.1056/NEJMoa1707914
37. Mazzone A., Parri M.S., Giannessi D., Ravani M., Vaghetti M., Altieri P., Casalino L., Maltinti M., Balbi M., Barsotti A., Berti S. Osteopontin plasma levels and accelerated atherosclerosis in patients with CAD undergoing PCI: a prospective clinical study. Coronary Artery Dis., 2011; 22 (3): 179–187. doi: 10.1097/MCA.0b013e3283441d0b
38. Afolabi A., Mustafina I., Zhao L., Li L., Sun R., Hu S., Zhang S., Jia H., Guilio G., Yu B. Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study. Catheter Cardiovasc. Interv., 2018; 91 (S1): 582–590. doi: 10.1002/ccd.27496
39. Skeoch S., Bruce I.N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat. Rev. Rheumatol., 2015; 11 (7): 390–400. doi: 10.1038/nrrheum.2015.40
40. Serhan C.N., Chiang N., Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin. Immunol., 2015; 27 (3): 200–215. doi: 10.1016/j.smim.2015.03.004
41. Nicholls S.J., Puri R., Anderson T., Ballantyne C.M., Cho L., Kastelein J.J.P., Koenig W., Somaratne R., Kassahun H., Yang J., Wasserman S.M., Scott R., Ungi I., Podolec J., Ophuis A.O., Cornel J.H., Borgman M., Brennan D.M., Nissen S. Effect of evolocumab on progression of coronary disease in statintreated patients: the GLAGOV randomized clinical trial. JAMA, 2016; 316 (22): 2373–2384. doi: 10.1001/jama.2016.16951
42. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D., Kastelein J.J.P., Cornel J.H., Pais P., Pella D., Genest J., Cifkova R., Lorenzatti A., Forster T., Kobalava Z., Vida-Simiti L., Flather M., Shimokawa H., Ogawa H., Dellborg M., Rossi P.R.F., Troquay R.P.T., Libby P., Glynn R.J. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med., 2017; 377 (12): 1119–1131. doi: 10.1056/NEJMoa1707914
43. Sen N. Cocaine cardiomyopathy, physicians should be aware and focused on management. J. Clin. Cardiol. Cardiovasc. Intervent., 2020; 3 (1). doi:10.31579/2641-0419/024
44. Welten S.M., Goossens E.A., Quax P.H., Nossent A.Y. The multifactorial nature of microRNAs in vascular remodeling. Cardiovasc. Res., 2016; 110 (1): 6–22. doi: 10.1093/cvr/cvw039
45. Chistiakov D.A., Sobenin I.A., Orekhov A.N., Bobryshev Y.V. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. Biomed. Res. Int., 2015; 2015: 354517. doi: 10.1155/2015/354517
Рецензия
Для цитирования:
Ложкина Н.Г., Пархоменко О.М. Атеросклероз спонтанный и прогрессирующий – есть ли разница? Атеросклероз. 2020;16(4):70-76. https://doi.org/10.15372/ATER20200409
For citation:
Lozhkina N.G., Parkhomenko O.M. Spontaneous and progressive atherosclerosis – is there a difference? Ateroscleroz. 2020;16(4):70-76. (In Russ.) https://doi.org/10.15372/ATER20200409
Просмотров:
347
Послать статью по эл. почте 